Patents by Inventor Matthew Parker

Matthew Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8865126
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: October 21, 2014
    Assignee: Endocyte, Inc.
    Inventors: Christopher P. Leamon, Matthew A. Parker
  • Patent number: 8834842
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 16, 2014
    Assignee: Endocyte, Inc.
    Inventors: Christopher P. Leamon, Matthew A. Parker
  • Publication number: 20140069026
    Abstract: In a rostrum, comprising a rostrum support structure comprising a plurality of frame units; the frame units comprising at least a first frame unit, a second frame unit which is retractable in a retraction direction from an extended position into the first frame unit, and a third frame unit, which is retractable in the retraction direction from an extended position into the second frame unit, a latching mechanism is provided which is configured so that the third frame unit cannot be retracted from the extended position into the second frame unit until the second frame unit has been retracted from the extended position into the first frame unit. A respective deck is engaged with each respective frame unit.
    Type: Application
    Filed: September 11, 2012
    Publication date: March 13, 2014
    Inventor: Nigel Matthew Parker
  • Publication number: 20140058063
    Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
    Type: Application
    Filed: March 5, 2013
    Publication date: February 27, 2014
    Applicant: ENDOCYTE, INC.
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna R. Santhapuram, Apparao Satyam, Joseph A. Reddy
  • Publication number: 20130255414
    Abstract: A stage apparatus includes at least one tube having a first section and a second section, the first section being coupled to a point of reference. The apparatus also includes at least one magnet, a precision stage, and a tube carrier. The precision stage is positioned at least partially over the at least one magnet, and has a first set of coils. The first set of coils cooperates with the at least one magnet to drive the precision stage. The tube carrier is at least partially positioned over the at least one magnet, and includes an end effector portion arranged to carry the second section, wherein the tube carrier further includes a second set of coils, the second set of coils being supported by the end effector portion and arranged to cooperate with the at least one magnet to control motion of the end effector portion.
    Type: Application
    Filed: September 8, 2011
    Publication date: October 3, 2013
    Applicant: Nikon Corporation
    Inventors: Matthew Parker-McCormick Bjork, Michael B. Binnard, Scott Coakley
  • Publication number: 20130237687
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Application
    Filed: October 18, 2012
    Publication date: September 12, 2013
    Applicant: ENDOCYTE, INC.
    Inventors: Christopher P. LEAMON, Matthew A. Parker
  • Patent number: 8343146
    Abstract: Embodiments of a system and method are described for delivering energy to a body of a human or animal through a plurality of energy delivery devices. In some embodiments, a plurality of energy delivery devices are coupled to a generator and the number of energy delivery devices is automatically detectable. Furthermore, in some embodiments, the amount of energy delivered through the energy delivery devices is controlled, at least in part, by dynamically varying the amount of time that each energy delivery device is delivering energy.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: January 1, 2013
    Assignee: Kimberly-Clark Inc.
    Inventors: Neil Godara, Taylor Hillier, Matthew Parker, Jason Woo
  • Patent number: 8313728
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: November 20, 2012
    Assignee: Endocyte, Inc.
    Inventors: Christopher P. Leamon, Matthew A. Parker
  • Patent number: 8298263
    Abstract: The technology disclosed herein provides a device, system, and method for weaning a child off a sucking device, such as a pacifier, by introducing a series of sucking devices with successively smaller nubs. A child is given a first sucking device having a nub of a certain size, and, after a time period, the child is given a second sucking device having a nub smaller than that of the first sucking device. This method may be repeated in multiple iterations, until the child is weaned off sucking devices.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: October 30, 2012
    Assignee: TinkLab, LLC
    Inventors: Matthew Parker, Timothy Ramundo
  • Publication number: 20120065149
    Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
    Type: Application
    Filed: September 7, 2011
    Publication date: March 15, 2012
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna Santhapuram, Apparao Satyam, Joseph Anand Reddy
  • Patent number: 8105568
    Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: January 31, 2012
    Assignee: Endocyte, Inc.
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna R. Santhapuram, Apparao Satyam, Joseph A. Reddy
  • Publication number: 20110063418
    Abstract: A device is described which allows convenient acquisition of stereoscopic video. In accordance with one embodiment, a rigid mounting bar is provided on which two camcorders can be mounted. The bar has mounting slots or other means to provide for adjustment of the distance between the two cameras. An electronic synchronization and control circuit is contained within the mounting bar. This circuit synchronizes the two camcorders quickly so that each video frame is acquired simultaneously by the two camcorders.
    Type: Application
    Filed: August 4, 2010
    Publication date: March 17, 2011
    Inventor: Matthew A. Parker
  • Patent number: 7862798
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: January 4, 2011
    Assignee: Endocyte, Inc.
    Inventors: Christopher P. Leamon, Matthew A. Parker
  • Publication number: 20100324548
    Abstract: Embodiments of a system and method are described for delivering energy to a body of a human or animal through a plurality of energy delivery devices. In some embodiments, a plurality of energy delivery devices are coupled to a generator and the number of energy delivery devices is automatically detectable. Furthermore, in some embodiments, the amount of energy delivered through the energy delivery devices is controlled, at least in part, by dynamically varying the amount of time that each energy delivery device is delivering energy.
    Type: Application
    Filed: February 25, 2008
    Publication date: December 23, 2010
    Applicant: BAYLIS MEDICAL COMPANY INC.
    Inventors: Neil Godara, Taylor Hillier, Matthew Parker, Jason Woo
  • Publication number: 20100069959
    Abstract: The technology disclosed herein provides a device, system, and method for weaning a child off a sucking device, such as a pacifier, by introducing a series of sucking devices with successively smaller nubs. A child is given a first sucking device having a nub of a certain size, and, after a time period, the child is given a second sucking device having a nub smaller than that of the first sucking device. This method may be repeated in multiple iterations, until the child is weaned off sucking devices.
    Type: Application
    Filed: September 9, 2009
    Publication date: March 18, 2010
    Applicant: TINKLAB, LLC
    Inventors: Matthew Parker, Timothy Ramundo
  • Publication number: 20100004276
    Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
    Type: Application
    Filed: July 10, 2009
    Publication date: January 7, 2010
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna Santhapuram, Apparao Satyam, Joseph Anand Reddy
  • Publication number: 20090324499
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Application
    Filed: September 11, 2009
    Publication date: December 31, 2009
    Applicant: Endocyte, Inc.
    Inventors: Christopher P. LEAMON, Matthew A. PARKER
  • Patent number: 7601332
    Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: October 13, 2009
    Assignee: Endocyte, Inc.
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna Santhapuram, Apparao Satyam, Joseph Anand Reddy
  • Publication number: 20080228181
    Abstract: Methods are disclosed for delivering energy to a body of a human or animal during a treatment procedure using an electrosurgical generator, a pre-set overall procedure time being defined for the treatment procedure, a ramp time being defined for a parameter to reach a pre-set threshold during the treatment procedure, the method comprising: measuring the parameter over time; and if the parameter has not substantially reached the pre-set threshold by the ramp time, setting a procedure extension time responsive to the time difference between the ramp time and the time at which the pre-set threshold was reached, and extending the overall procedure time by the procedure extension time.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 18, 2008
    Applicant: Baylis Medical Company
    Inventors: Neil GODARA, Taylor Hillier, Matthew Parker, Hua Xin Lo, Jason Woo
  • Publication number: 20070031334
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Application
    Filed: October 11, 2006
    Publication date: February 8, 2007
    Inventors: Christopher Leamon, Matthew Parker